Literature DB >> 2642730

A controlled trial of extended radical versus radical mastectomy. Ten-year results.

P Meier1, D J Ferguson, T Karrison.   

Abstract

In view of increasing debate over possible benefit of more complete surgery compared to conservative procedures, a randomized controlled trial contrasting the then standard Halsted radical (RDL) operation with the more complete extended radical (EXT) mastectomy was initiated in 1973. Between November 1973 and July 1982, 123 women younger than 70 years of age and at clinical Stages I and II were enrolled. Of the total series, 112 were treated by the same surgeon and confirmed pathologically as having invasive mammary carcinoma. In this more homogeneous subgroup, the 10-year survival rates (and standard errors) were for RDL, 60% (+/- 7%) and for EXT, 74% (+/- 6%) (P value for comparison of survival curves = 0.13). In patients from this subgroup with central-medial tumors, comprising 62% of the total, survival after RDL at 10 years was 60% (+/- 8%), and after EXT 86% (+/- 6%) (P = 0.025). In the remaining patients with lateral tumors, survival rates were unaffected by treatment: 58% (+/- 13%) and 56% (+/- 11%), respectively (P = 0.62). Comparison of a nonrandomized series of 266 RDL and 124 EXT patients treated between 1960 and 1978 found differences consistent with those of the randomized study, although not statistically significant.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2642730     DOI: 10.1002/1097-0142(19890101)63:1<188::aid-cncr2820630130>3.0.co;2-m

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  17 in total

1.  Controversies in the Surgical Management of Operable Breast Cancer.

Authors: 
Journal:  Breast Cancer       Date:  1994-12-30       Impact factor: 4.239

2.  Have changing treatment patterns affected outcome for operable breast cancer? Ten-year follow-up in 1288 patients, 1965 to 1978.

Authors:  H S Cody; E H Laughlin; C Trillo; J A Urban
Journal:  Ann Surg       Date:  1991-04       Impact factor: 12.969

Review 3.  Postmastectomy radiotherapy in women with breast cancer metastatic to one to three axillary lymph nodes.

Authors:  C I Sartor
Journal:  Curr Oncol Rep       Date:  2001-11       Impact factor: 5.075

4.  Unplanned irradiation of internal mammary lymph nodes in breast cancer.

Authors:  Gul Kanyilmaz; Meryem Aktan; Mehmet Koc; Hikmettin Demir; Lütfi Saltuk Demir
Journal:  Radiol Med       Date:  2017-03-03       Impact factor: 3.469

5.  Breast cancer screening for women younger than 40.

Authors:  A F Gili; Z Poonja; B B Kalra
Journal:  Can Fam Physician       Date:  1993-01       Impact factor: 3.275

6.  Internal mammary node status: a major prognosticator in axillary node-negative breast cancer.

Authors:  H S Cody; J A Urban
Journal:  Ann Surg Oncol       Date:  1995-01       Impact factor: 5.344

7.  Radical mastectomy with parasternal node dissection or radiation to the parasternal region for breast cancer of medial or central location.

Authors:  E Shiba; K Miyauchi; T Kobayashi; S Takai; T Mori
Journal:  Surg Today       Date:  1992       Impact factor: 2.549

8.  The effect of adjuvant radiotherapy on mortality differs according to primary tumor location in women with node-positive breast cancer.

Authors:  Vincent Vinh-Hung; Pauline T Truong; Wolfgang Janni; Nam Phong Nguyen; Georges Vlastos; Gábor Cserni; Melanie E Royce; Wendy A Woodward; Donald Promish; Patricia Tai; Guy Soete; Sabine Balmer-Majno; Bruno Cutuli; Guy Storme; Christine Bouchardy
Journal:  Strahlenther Onkol       Date:  2009-03-28       Impact factor: 3.621

9.  Reappraisal of internal mammary lymph node dissection in selected patients with invasive breast cancer.

Authors:  M Noguchi; H Kitagawa; K Kinoshita; M Earashi; I Miyazaki
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

10.  The Metastatic Rate of Internal Mammary Lymph Nodes When Metastasis of Internal Mammary Lymph Node Is Suspected on PET/CT.

Authors:  Jung Eun Choi
Journal:  J Breast Cancer       Date:  2013-06-28       Impact factor: 3.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.